USPTO serial 98785584
EXPEDITION
Reviewed by CopyMark Law Group
Status 730Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- NGUYEN, ANGELA G
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with EXPEDITION?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $697*
Plus Government fees of $375
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christina M. Licursi
Christina M. Licursi Wolf, Greenfield & Sacks, P.C.600 Atlantic AvenueBoston, MA 02210-2206United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of viral, bacterial, fungal, parasitic, prion based, metabolic, endocrine, cardiovascular, cardiopulmonary, sexual dysfunction, hepatological, ophthalmic, neurological, hormonal, psychiatric, genetic, rare, hematological, musculoskeletal, renal, nutritional, otolaryngological, pediatric, developmental, and pain-related diseases and disorders; therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of viral, bacterial, fungal, parasitic, prion based, metabolic, endocrine, cardiovascular, cardiopulmonary, sexual dysfunction, hepatological, ophthalmic, neurological, hormonal, psychiatric, genetic, rare, hematological, musculoskeletal, renal, nutritional, otolaryngological, pediatric, developmental, and pain-related diseases and disorders; protein-based and small molecule therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, sexual dysfunction, hepatological, ophthalmic, neurological, hormonal, psychiatric, genetic, rare, hematological, musculoskeletal, renal, nutritional, otolaryngological, pediatric, developmental, and pain-related diseases and disorders; protein based and small molecule pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, sexual dysfunction, hepatological, ophthalmic, neurological, hormonal, psychiatric, genetic, rare, hematological, musculoskeletal, renal, nutritional, otolaryngological, pediatric, developmental, and pain-related diseases and disorders; pharmaceuticals for the diagnosis of cancer, genitourinary, oncological, respiratory, gastrointestinal, dermatological, immune system-related, autoimmune, rheumatological, and age-related diseases and disorders; therapeutics, namely, therapeutic agents for the diagnosis of cancer, genitourinary, oncological, respiratory, gastrointestinal, dermatological, immune system-related, autoimmune, rheumatological, and age-related diseases and disorders; protein-based and small molecule therapeutics, namely, therapeutic agents for the diagnosis of cancer, genitourinary, oncological, respiratory, gastrointestinal, dermatological, immune system-related, autoimmune, rheumatological, and age-related diseases and disorders; protein-based and small molecule pharmaceuticals for the diagnosis of cancer, genitourinary, oncological, respiratory, gastrointestinal, dermatological, immune system-related, autoimmune, rheumatological, and age-related diseases and disorders; protein-based therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, or management of cancer, genitourinary, oncological, respiratory, gastrointestinal, dermatological, immune system-related, autoimmune, rheumatological, and age-related diseases and disorders; protein-based pharmaceuticals for the treatment, prevention, mitigation, or management of cancer, genitourinary, oncological, respiratory, gastrointestinal, dermatological, immune system-related, autoimmune, rheumatological, and age-related diseases and disorders | ACTIVE | — |
| 009 | Downloadable software for use in the pharmaceuticals and healthcare fields, namely, for enabling and facilitating molecular research, research and development of pharmaceutical products and chemical compounds, design of chemical structures, and analysis of biological or chemical activity; downloadable software for providing life science analytics | ACTIVE | — |
| 042 | Scientific research, namely, research and analysis services for the design and characterization of biologic therapeutic products; research services in the fields of genomic and transcriptomic analysis; genomic analysis and sequencing services for scientific and research purposes; medical and scientific research in the fields of genetics, genomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; research, development, and consultancy in the field of genomics; consultancy in the field of proteomics; medical research, namely, compiling data for research purposes in the field of genomics; Software as a service (SAAS) services featuring software using artificial intelligence for use in the fields of healthcare for enabling and facilitating molecular research, research and development of pharmaceutical products and chemical compounds, design of chemical structures, and analysis of biological or chemical activity; software as a service (SAAS) services featuring software using artificial intelligence for use in the biotechnology field for discovering and designing biomolecules and chemical structures; software as a service (SAAS) services featuring software using artificial intelligence, computational methods, and machine learning models for data analysis in the fields of biomedical and genomic research; providing temporary use of on-line non downloadable software featuring artificial intelligence, computational methods, and machine learning models for the design and characterization of biologic therapeutic products and drug analysis in drug discovery and development; DNA analysis and sequencing services for scientific and research purposes; providing on-line non downloadable software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta genomics, meta-transcriptomics, and microbiomics; platform as a service (PaaS) featuring computer software platforms for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, and meta-transcriptomics | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Flagship Labs 94, Inc.
- Other trademarks owned by EXPEDITION MEDICINES, INC.
- Other trademarks owned by EXPEDITION MEDICINES, INC.
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named EXPEDITION
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 26, 2026 | NOAC | CORRECTED NOA E-MAILED | — |
| May 26, 2026 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| May 2, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 12, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 11, 2025 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Dec 11, 2025 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Dec 11, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 11, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 11, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 11, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 16, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 16, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 10, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 14, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 31, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 31, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 31, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 1, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 1, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 1, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 9, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 3, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 5, 2025 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Oct 4, 2024 | NWAP | NEW APPLICATION ENTERED | — |